| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenue for the current quarter has increased by 4.5% compared to the same quarter of the last year, driven by increase in volumes across key markets, new brand additions, price revisions, and continued momentum in high-value therapeutic areas and key markets. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit increased by 12.3% during the current quarter compared to the same quarter of the last year primarily driven by enhanced operating leverage supported by one-offs including lower provisions, and net financial income. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Revenue for the current quarter has declined by 13.6% compared to 2Q 2025, as 3Q sales are generally lower than 2Q due to strategic seasonality skewed towards 1H25. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | The Company’s net profit decreased by 19.2% during the current quarter compared to 2Q 2025, mainly due to the lower revenue, increase in depreciation expenses pertaining to capitalized assets in the first and second Quarter of 2025 and increased repair & maintenance. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Revenue during the current period has increased by 13.0% compared to the same period of the last year, driven by the Company’s focus on high-value strategic brands, core therapeutic areas, and targeted expansion in key markets, growth remained primarily volume-led, supported by new brand launches and net positive price revisions. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net profit during the current period has increased by 29.8% compared to the same period of the last year, driven by improved revenue performance resulting in better operating leverage, absence of significant financial charges, one-off other income, and reduced ECL provisions offsetting lower JV income. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | The Group’s consolidated financial statements for the year ended 31 December 2024 were audited by another auditor who expressed an unmodified opinion on those consolidated financial statements on 4 March 2025 (corresponding to 4 Ramadhan 1446H). Further, the interim condensed consolidated financial statements of the Group for the three-month and nine-month periods ended 30 September 2024 were reviewed by another auditor who expressed an unmodified review conclusion on interim condensed consolidated financial statements on 31 October 2024 (corresponding to 28 Rabi Al Thani 1446H). |
| Reclassification of Comparison Items | None |
| Additional Information | Please refer to the attached Earnings Release for detailed information on the 9M 2025 results. |
| Attached Documents |  |